Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Avenzo Therapeutics provides corporate update and announces closing of $150 million Series A/A-1 financing to advance its clinical-stage oncology pipeline. The…
VelaVigo secures an exclusive licensing option for a Nectin4/TROP2 bispecific antibody-drug conjugate with Avenzo Therapeutics. The bispecific ADC targets two…
FDA granted Fast Track designation to AVZO-103 for adult patients with locally advanced or metastatic urothelial cancer previously treated with enfortumab…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Avenzo Therapeutics entered an exclusive option agreement with VelaVigo (Nov 25, 2024) for global (ex-Greater China) rights to a first-in-class Nectin-4/TROP2 bispecific ADC (AVZO-103, formerly VAC-103). Terms: upfront plus near-term option-exercise milestones up to $50M and up to $750M in development/regulatory/commercial milestones plus tiered royalties. On Sept 2, 2025 Avenzo announced it had EXERCISED its exclusive option from VelaVigo - securing global ex-Greater China development, manufacturing and commercialization rights - concurrent with FDA clearance of the AVZO-103 IND. Avenzo initiated the BEACON-1 Phase 1/2 first-in-human study (NCT07193511; 355 patients planned) on Oct 2, 2025 in locally advanced or metastatic urothelial cancer and other solid tumors. On Nov 24, 2025 the FDA granted AVZO-103 Fast Track designation for la/mUC previously treated with enfortumab vedotin (Padcev), a population with no approved ADCs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Avenzo Therapeutics Inc. / VelaVigo Bio Inc. (this deal) | 2024 | $800M | — |
| Avenzo Therapeutics Inc. / Duality Biotherapeutics, Inc. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2024 deals · Oncology deals